-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
-
Summary
-
Arrowhead Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q3 2013 to Q3 2024.
- Arrowhead Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending September 30, 2024 was $449M, a 57.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)